Interestingly, a recent study reported that concomitant inhibition of both MARK2 and MARK3 is required to prevent YAP/TAZ function in diverse carcinoma and sarcoma contexts, highlighting the redundant nature of MARK family members. The gene discussed is MARK2; the disease is sarcoma.